Technical Specification for Hemocompatibility Assessment of Human Mesenchymal Stem Cells

Jialing Liu, Weiyang Liang, Wenjie Xia, Ping Wang, Jie Hao, Tao Na, Sunxing Yan, Yu Alex Zhang, Ka Li, Qiyuan Li, Guangjin Pan, Jun Wei, Qubo Chen, Jiani Cao, Peijun Zhai, Boqiang Fu, Hengjun Gao, Yong Zhang, Lei Wang, Meimei Guo, Shijun Hu, Lijun Zhu, Yi Zhao, Wen Zhang, Zhihong Wu, Yifang Ping, Hongling Zhao, ShuaiShuai Niu, TongBiao Zhao, Aijin Ma, Andy Peng Xiang, Xiaoyong ChenCell 2026 · DOI

TL;DR

This paper introduces the first technical specification in China for assessing the hemocompatibility of human mesenchymal stem cells (MSCs). It provides a standardized framework for evaluating how MSCs interact with blood, aiming to ensure their safety and efficacy in clinical applications and accelerate international standardization.

What Problem Does This Paper Address?

Mesenchymal stem cells (MSCs) hold immense therapeutic potential, but their use in clinical settings requires rigorous safety assessments, particularly concerning their interaction with blood. Without standardized protocols, inconsistencies in hemocompatibility testing can lead to unreliable results, hindering the translation of MSC-based therapies into widespread clinical practice. This paper addresses the critical need for a unified, China-specific standard to guide the assessment of MSC hemocompatibility, ensuring that these cells do not induce adverse blood reactions like coagulation or platelet activation before they come into contact with the bloodstream.

Methods

The core of this paper is the establishment of a technical specification that outlines a comprehensive approach to hemocompatibility assessment. This involves:

  • Defining Key Indicators: The specification identifies eight critical evaluation indicators across five categories: protein expression (Tissue Factor), coagulation tests (TAT), platelet activation tests (β-TG, PF4, TxB2), complement activation tests (SC5b-9, C3a), and thrombosis tests (in vivo thrombosis).
  • Standardizing Calculation Methods: For each indicator, the paper details specific calculation methods and data sources, ensuring consistency in how results are derived. For instance, Tissue Factor assessment involves measuring the percentage of TF-positive cells, while coagulation and platelet activation are assessed via ratios of specific markers in test samples compared to control samples.
  • Establishing Compatibility Levels: A crucial aspect is the classification of compatibility levels into "poor" and "good" based on predefined thresholds for each evaluation factor. This allows for a clear determination of the overall hemocompatibility of MSCs.
  • In Vivo and In Vitro Assessments: The specification mandates both in vitro and in vivo assessments to provide a comprehensive understanding of hemocompatibility.

Datasets

Not discussed in the paper. The paper focuses on establishing a standard methodology rather than presenting results from a specific dataset.

Key Insights and Ideas

  • The Need for Standardization: The paper strongly emphasizes that a lack of standardized hemocompatibility testing is a significant bottleneck in the clinical translation of MSCs. This specification aims to bridge that gap.
  • Multifaceted Assessment: Hemocompatibility is not a single parameter but a complex interplay of various blood components. The specification's inclusion of protein expression, coagulation, platelet activation, complement activation, and thrombosis tests reflects this complexity.
  • Bridging In Vitro and In Vivo: The requirement for both in vitro and in vivo assessments is critical. While in vitro tests offer convenience and control, in vivo models provide a more realistic representation of how MSCs might behave in a living organism.
  • Clear Dichotomy in Compatibility: The classification into "poor" and "good" compatibility levels provides a straightforward, actionable outcome for researchers and developers.

Key Results

The paper's primary "result" is the establishment of the technical specification itself. It provides a detailed framework for:

  • Evaluation Indicators: A defined list of indicators (e.g., Tissue Factor, TAT, β-TG, PF4, TxB2, SC5b-9, C3a, In vivo thrombosis).
  • Calculation Methods: Specific formulas and data sources for each indicator.
  • Compatibility Criteria: Thresholds to classify each factor as "poor" or "good" compatibility. For example, a Tissue Factor expression rate > 10% is considered "poor," while ≤ 10% is "good." Similarly, for TAT, a ratio ≤ 80% or ≥ 120% indicates "poor" compatibility, while 80% < Ratio < 120% is "good."
  • Overall Hemocompatibility Determination: The lowest compatibility level among all evaluated factors determines the overall hemocompatibility of the MSCs. A "poor" level signifies a high probability of adverse blood reactions.

Limitations and Future Work

  • Scope of Application: While the specification is for human MSCs, the paper notes that the MSCs to be evaluated can be isolated from various tissues (bone marrow, umbilical cord, placenta, etc.) and can also be obtained through differentiation or transdifferentiation. The effectiveness of this standard across all these sources will be a point of future validation.
  • International Standardization: The authors express anticipation that this specification will accelerate international standardization, implying that further collaboration and harmonization with global standards will be a future endeavor.
  • Data Availability: The paper mentions that supporting information, including detailed protocols for each assay, is available online. This suggests that the practical implementation and refinement of these methods will be an ongoing process.

Summary updated

Abstract

'Technical specification for haemocompatibility assessment of human mesenchymal stem cells' is the first set of guidelines on haemocompatibility assessment of human mesenchymal stem cells (MSCs) in China, jointly drafted and agreed upon by experts from the Chinese Society for Stem Cell Research. This standard outlines the methods for assessing the hemocompatibility of human mesenchymal stem cells and specifies the requirements for the selection of evaluation indicators, calculation of indicator values, and determination of hemocompatibility levels. It is applicable for evaluating the hemocompatibility of MSCs prior to their contact with blood. This guideline was originally released by the Chinese Society for Cell Biology on October 28, 2024. We anticipate that the publication of this specification will promote the institutional adoption, acceptance, and execution of proper testing protocols, thereby accelerating the international standardization of MSCs for clinical development and therapeutic applications.
BibTeX
@inproceedings{liu2026technical,
  author = {Jialing Liu and Weiyang Liang and Wenjie Xia and Ping Wang and Jie Hao and Tao Na and Sunxing Yan and Yu Alex Zhang and Ka Li and Qiyuan Li and Guangjin Pan and Jun Wei and Qubo Chen and Jiani Cao and Peijun Zhai and Boqiang Fu and Hengjun Gao and Yong Zhang and Lei Wang and Meimei Guo and Shijun Hu and Lijun Zhu and Yi Zhao and Wen Zhang and Zhihong Wu and Yifang Ping and Hongling Zhao and ShuaiShuai NIU and TongBiao ZHAO and Aijin Ma and Andy Peng Xiang and Xiaoyong Chen},
  title = {{Technical Specification for Hemocompatibility Assessment of Human Mesenchymal Stem Cells}},
  booktitle = {Cell},
  year = {2026},
  doi = {10.1111/cpr.70183},
}
Figure